THREE HIGHLY INFORMATIVE MICROSATELLITE REPEAT POLYMORPHIC DNA MARKERS

Abstract: The invention relates to polymorphic markers (two tetranucleotide, one dinucleotide repeat polymorphisms and 27 markers characterized by primer pairs 1A-27A) that are useful for human individualization. Applications are in forensic medicine and for paternity and prenatal screening as well as genetic mapping. These markers ae characterized by sets of oligonucleotide primers according to the invention useful in PCR amplification and DNA segment resolution. The invention further relates to an assay for measuring the subtle differences in genetic material regarding an added or omitted set of dinucleotide or tetranucleotide repeat polymorphisms which comprises obtaining an amount of nucleotide segments effective for testing, amplifying the segments by the PCR procedure using at least one primer nucleotide sequence according to the present invention, resolving the amplified segments using gel electrophoresis, and comparing the resolved segments by autoradiography to observe the differences in migration patterns due to structural differences. The assay according to the invention is easy to perform and results can be obtained within 24 hours. It is not uncommon for results to be available within 3-4 hours. Accordingly, the invention also relates to an improved PCR procedure and a PCR assay kit which comprise nucleotides according to the invention.

Description: THREE HIGHLY INFORMATIVE MICROSATELLITE REPEAT POLYMORPHIC DNA MARKERS Technical Field This application relates to genetic testing with polymorphic DNA markers having repeat sequences to provide a rapid and convenient high resolution process for distinguishing target nucleic acid segments on the basis of nucleotide differences according to human individualization wherein the nucleic acid segments differ in size. Background Art The science of genetics has taken a keen interest in the identification of human individualization and genetic relationships between individuals. Each individual has hereditary material (DNA, "nucleotides" ) which is unique to that individual and hereditary material which is related to that of others. Procedures have been developed which are based on identification and characterization of changes in DNAs, which are changes in DNA (DNA polymorphisms) due to nucleotide substitution, insertion, or deletion within the chains of DNAs. In the field of forensic medicine , for example, there is a keen interest in such polymorphisms for identification purposes . Forensic geneticist have developed many techniques to compare homologous segments of DNA to determine if the segments are identical or if they differ in one or more nucleotides . Practical applications of these techniques relate to fields other than forensic medicine, for example, genetic disease diagnosis and human genome mapping. At the present time in this art, the most accurate and informative way to compare DNA segments requires a method which provides the complete nucleotide sequence for each DNA segment. Particular techniques have been developed for determining actual sequences in order to study mutation in human genes. See, for example, Proc. Natl. Acad. Sci. U.S.A. j_5_, 544-548 (1988) and Nature 330, 384-386 (1987). However, because of the extensive amounts of time and high costs to determine, interpret, and compare sequence information, presently it is not practical to use extensive sequencing for compare more than just a few DNA segments. In genetic mapping, the most frequently used screening for DNA polymorphisms arising from mutations consist of digesting the DNA strand with restriction endonucleases and analyzing the resulting fragments by means of Southern blots. See Am. J. Hum. Genet. 32, 314-331 (1980) or Sci. Am. J258., 40-48 (1988). Since mutations often occur randomly they may affect the recognition sequence of the endonuclease and preclude the enzymatic cleavage at that cite. Restriction fragment length polymorphism mappings (RFLPS) are based on changes at the restriction site. They are accurate but not very informative (PIC [ 0.3). The major problem with RFLPs is the inability of a test to detect changes that do not affect cleavage with a restriction endonuclease. As in many of the test methods in the DNA art, the methods used to detect RFLPs are very labor intensive and expensive, especially the techniques which includes Southern blot analysis. Another technique for detecting specific mutations in particular DNA segment involves hybridizing DNA segments which are being analyzed (target DNA) with a complimentary, labeled oligonucleotide probe. See Nucl. Acids Res. 9., 879-894 (1981). Since DNA duplexes containing even a single base pair mismatch exhibit high thermal instability, the differential melting temperature can be used to distinguish target DNAs that are perfectly complimentary to the probe from target DNAs that only differ by a single nucleotide. This method has been adapted to detect the presence or absence of a specific restriction site, U.S. Patent No. 4,683,194. The method involves using an end-labeled oligonucleotide probe spanning a restriction site which is hybridized to a target DNA. The hybridized duplex of DNA is then incubated with the restriction enzyme appropriate for that site. Reformed restriction sites will be cleaved by digestion in the pair of duplexes between the probe and target by using the restriction endonuclease. The specific restriction site is present in the target DNA if shortened probe molecules are detected. Another process for studying differences in DNA structure is the primer extension process which consists of hybridizing a labeled oligonucleotide primer to a template RNA or DNA and then using a DNA polymerase and deoxynucleoside triphosphates to extend the primer to the 5' end of the template. Resolution of the labeled primer extension product is then done by fractionating on the basis of size, e.g. , by electrophoresis via a denaturing polyacry1amide gel. This process is often used to compare homologous DNA segments and to detect differences due to nucleotide insertion or deletion. Differences due to nucleotide substitution are not detected since size is the sole criterion used to characterize the primer extension product. Another process exploits the fact that the incorporation of some nucleotide analogs into DNA causes an incremental shift of mobility when the DNA is subjected to a size fractionation process, such as electrophoresis. Nucleotide analogs can be used to identify changes since they can cause an electro- phoretic mobility shift. See, U.S. Patent 4,879,214. Unfortunately, the above techniques used for identification of polymorphisms are either not very informative or take a long period of time to perform. For example, techniques which identify changes in individual nucleotides on a particular DNA strand often take at least three to four days to perform. Accordingly, such tests are very labor intensive and expensive to perform. Further, subtle genetic differences among related individuals regarding nucleotides which are substituted in the DNA chains are difficult to detect. VNTR's or Jeffrey's probes (which the FBI is using to test and identify DNA chains) are very informative but labor intensive, in distinction to microsatellites as our which are equally informative PCR based polymormismic. The use of certain nucleotide repeat polymorphisms for identifying or- comparing DNA segments have been described by Weber & May 89 Am Hum Genet 44:388, Litt & Luthy '89 Am) Hum Genet 44:397). However the particular polymorphism genetic segments and primers used to identify the polymorphisms (for identification and comparison purposes) of the present invention have not been previously known or suspected. Accordingly, there a need in this art for a rapid, simple, inexpensive and accurate technique having a very high resolution value to determine relationships between individuals and differences in degree of relationships. Also, there is a need in the art for a very accurate genetic relationship test procedure which uses very small amounts of an original DNA sample, yet produces very accurate results. This is particularly true in the forensic medicine area and criminology, since often times very small samples of DNA are available for testing. Disclosure of the Invention An object of the present invention is to provide a fast and accurate test for measuring the subtle differences in individuals by way of genetic testing. Another object of the invention relates to polymorphic markers that can be used for human individualization. A further object of the invention is to provide a fast and accurate technique for measuring the subtle differences in individuals by way of genetic testing that can be applied in multiple areas, e.g. , forensic screening, paternity and prenatal screening and genetic mapping. A still further object is to provide an improved method for conducting a PCR procedure using an effective amount of a nucleotide according to the present invention and to provide an PCR assay kit comprising • an effective amount of a nucleotide according to the present invention and ancillary PCR reagents. Brief Description of Drawings Figure 1 relates to a nucleotide sequence according to SEQ ID N0:1. Figure 2 relates to a nucleotide sequence according to SEQ ID NO:2. Figure 3 relates to a nucleotide sequence according to SEQ ID NO:3. Figure 4 relates to a nucleotide sequence according to SEQ ID NO:4. Figure 5 relates to a nucleotide sequence according to SEQ ID NO:5. Figure 6 relates to a nucleotide sequence according to SEQ ID NO:6. Figure 7 relates to a nucleotide sequence according to SEQ ID NO:7. Figure 8 relates to a nucleotide sequence according to SEQ ID NO:8. Figure 9 relates to a nucleotide sequence according to SEQ ID NO:9. Figure 10 relates to a nucleotide sequence according to SEQ ID NO:10. Figure 11 relates to a nucleotide sequence according to SEQ ID NO:11. Figure 12 relates to a nucleotide sequence according to SEQ ID NO:12. Figure 13 relates to a nucleotide sequence according to SEQ ID NO:13. Figure 14 relates to a nucleotide sequence according to SEQ ID NO:14. Figure 15 relates to a nucleotide sequence according to SEQ ID NO:15. Figure 16 relates to a nucleotide sequence according to SEQ ID NO:16. Figure 17 relates to a nucleotide sequence according to SEQ ID NO:17. Figure 18 relates to a nucleotide sequence according to SEQ ID NO:18. Figure 19 relates to a nucleotide sequence according to SEQ ID NO:19. Figure 20 relates to a nucleotide sequence according to SEQ ID NO:20. Figure 21 relates to a nucleotide sequence according to SEQ ID NO:21. Figure 22 relates to a nucleotide sequence according to SEQ ID NO:22. Figure 23 relates to a nucleotide sequence according to SEQ ID NO:23. Figure 24 relates to a nucleotide sequence according to SEQ ID NO:24. Figure 25 relates to a nucleotide sequence according to SEQ ID NO:25. Figure 26 relates to a nucleotide sequence according to SEQ ID NO:26. Figure 27 relates to a nucleotide sequence according to SEQ ID NO:27. Figure 28 relates to a nucleotide sequence according to SEQ ID NO:28. Figure 29 relates to a nucleotide sequence according to SEQ ID NO:29. Figure 30 relates to a nucleotide sequence according to SEQ ID NO:30. Figure 31 relates to a nucleotide sequence according to SEQ ID NO:31. Figure 32 relates to a nucleotide sequence according to SEQ ID NO:32. Figure 33 relates to a nucleotide sequence according to SEQ ID NO:33. Figure 34 relates to a nucleotide sequence according to SEQ ID NO:34. Figure 35 relates to a nucleotide sequence according to SEQ ID NO:35. Figure 36 relates to a nucleotide sequence according to SEQ ID NO:36. Figure 37 relates to a nucleotide sequence according to SEQ ID NO:37. Figure 38 relates to a nucleotide sequence according to SEQ ID NO:38. Figure 39 relates to a nucleotide sequence according to SEQ ID NO:39. Figure 40 relates to a nucleotide sequence according to SEQ ID NO:40. Figure 41 relates to a nucleotide sequence according to SEQ ID NO:41. Figure 42 relates to a nucleotide sequence according to SEQ ID NO:42. Figure 43 relates to a nucleotide sequence according to SEQ ID NO:43. Figure 44 relates to a nucleotide sequence according to SEQ ID NO:44. Figure 45 relates to a nucleotide sequence according to SEQ ID NO:45. Figure 46 relates to a nucleotide sequence according to SEQ ID NO: 6. Figure 47 relates to a nucleotide sequence according to SEQ ID NO:47. Figure 48 relates to a nucleotide sequence according to SEQ ID NO:48. Figure 49 relates to a nucleotide sequence according to SEQ ID NO:49. Figure 50 relates to a nucleotide sequence according to SEQ ID NO:50. Figure 51 relates to a nucleotide sequence according to SEQ ID NO:51. Figure 52 relates to a nucleotide sequence according to SEQ ID NO:52. Figure 53 relates to a nucleotide sequence according to SEQ ID NO:53. Figure 54 relates to a nucleotide sequence according to SEQ ID NO:54. Figure 55 relates to a nucleotide sequence according to SEQ ID NO:55. Figure 56 relates to a nucleotide sequence according to SEQ ID NO:56. Figure 57 relates to a nucleotide sequence according to SEQ ID NO:57. Figure 58 relates to a nucleotide sequence according to SEQ ID NO:58. Figure 59 relates to a nucleotide sequence according to SEQ ID NO:59. Figure 60 relates to a nucleotide sequence according to SEQ ID NO:60. Figure 61 relates to a nucleotide sequence according to SEQ ID NO:61. Figure 62 relates to a nucleotide sequence according to SEQ ID NO:62. Figure 63 relates to a nucleotide sequence according to SEQ ID NO:63. Best Mode for Carrying out the Invention The present invention provides a fast and accurate test for measuring subtle genetic differences in individuals by way of genetic testing. The invention further relates to polymorphic markers (two tetranucleotide and one dinucleotide repeat polymorphisms) that can be used for human individualization. The invention further relates to 27 other polymorphic markers useful for human individualization. Applications for the technique and markers according to the invention are for example, in forensic screening, in paternity and prenatal screening as well as in genetic mapping. The invention relates to polymorphic markers (two tetranucleotide, one dinucleotide repeat polymorphisms and 27 other unique polymorphic markers) that are useful for human individualization of forensic screen, and for paternity and prenatal screening as well as genetic mapping. The markers according to the present invention have high polymorphism information content (PIC) values. The first three markers are characterized by sets of oligonucleotide primers as follows: 1. Set 1, PIC 0.92 a. A nucleotide sequence according to SEQ ID NO:l b. A nucleotide sequence according to SEQ ID NO:2 2. Set 2, PIC 0.91 a. A nucleotide sequence according to SEQ ID NO:3 b. A nucleotide sequence according to SEQ ID NO:4 3. Set 3, PIC 0.92 a. A nucleotide sequence according to SEQ ID NO:5 b. A nucleotide sequence according to SEQ ID NO:6. These polymorphic markers (two tetranucleotide and one dinucleotide repeat polymorphisms which are also accompanied by beginning and ending nucleotide sequences ) that can be used for human individualization are further characterized by the following marker sequences . 1. A nucleotide sequence having a repeat polymorphism according to SEQ ID NO:7. 2. A nucleotide sequence having a repeat polymorphism according to SEQ ID NO:8. 3. A nucleotide sequence having a repeat polymorphism according to SEQ ID NO:9. Since a polymorphic marker and an index locus occur as a "pair" , attaching a primer oligonucleotide according to the present invention to the polymorphic marker allows PCR amplification of the segment pair. The amplified DNA segment can then be resolved by electrophoresis and autoradiography. A resulting autoradiography can then be analyzed for its similarity to another DNA segment autoradiography. Following the PCR amplification procedure, electrophoretic motility enhancing DNA analogs may optionally be used to increase the accuracy of the electrophoresis step. Twenty-seven other primary pair sequences for detecting unique polymorphisms are sequences according to SEQ ID NO:10 through SEQ ID NO:63. The described polymorphisms are useful for human sample individualization, because of their high PIC values. Since the described polymorphisms are based on the polymerase chain reaction, only minute amounts of genomic DNA are required for each test. The target sequences range from 69-260 bps in length so that high molecular weight DNA is not necessary and common problems such as shearing of DNA will have minimal impact on the performance of the assay. The assay is easy to perform and results can be obtained within 24 hours. Microsatellite repeat polymorphisms have been shown to be useful tools in DNA analysis. The 27 polymorphisms described here are original and are based on previously sequenced human genes. The most commonly used technique in forensic screening is based on minisatellite markers in distinction to the PCR able icrosatellites described here. The 27 markers are characterized by sets of oligonucleotide primers as follows: Also, the invention relates to a method for conducting a PCR procedure comprising using an effective amount of at least one nucleotide according to according to the invention as set forth above, wherein the nucleotide is part of a primer pair of nucleotides selected from the group of nucleotide pairs consisting of a) a nucleotide sequence having the sequence as set forth in SEQ ID N0:1 and a nucleotide sequence as set forth in SEQ ID NO:2; b) a nucleotide sequence having the sequence as set forth in SEQ ID NO:3 and a nucleotide sequence as set forth in SEQ ID NO:4; c) a nucleotide sequence having the sequence as set forth in SEQ ID NO:5 and a nucleotide sequence as set forth in SEQ ID NO:6; d) a nucleotide sequence having the sequence as set forth in SEQ ID NO:10 and a nucleotide sequence as set forth in SEQ ID NO:11; e) a nucleotide sequence having the sequence as set forth in SEQ ID NO:12 and a nucleotide sequence as set forth in SEQ ID NO:13; f) a nucleotide sequence having the sequence as set forth in SEQ ID NO:14 and a nucleotide sequence as set forth in SEQ ID NO:15; g) a nucleotide sequence having the sequence as set forth in SEQ ID NO:16 and a nucleotide sequence as set forth in SEQ ID NO:17; h) a nucleotide sequence having the sequence as set forth in SEQ ID NO:18 and a nucleotide sequence as set forth in SEQ ID NO:19; i) a nucleotide sequence having the sequence as set forth in SEQ ID NO:20 and a nucleotide sequence as set forth in SEQ ID NO:21; j ) a nucleotide sequence having the sequence as set forth in SEQ ID NO:22 and a nucleotide sequence as set forth in SEQ ID NO:23; ) a nucleotide sequence having the sequence as set forth in SEQ ID NO:24 and a nucleotide sequence as set forth in SEQ ID NO:25; 1) a nucleotide sequence having the sequence as set forth in SEQ ID NO:26 and a nucleotide sequence as set forth in SEQ ID NO:27; m) a nucleotide sequence having the sequence as set forth in SEQ ID NO:28 and a nucleotide sequence as set forth in SEQ ID NO:29; n) a nucleotide sequence having the sequence as set forth in SEQ ID NO:30 and a nucleotide sequence as set forth in SEQ ID NO:31; o) a nucleotide sequence having the sequence as set forth in SEQ ID NO:32 and a nucleotide sequence as set forth in SEQ ID NO:33; p) a nucleotide sequence having the sequence as set forth in SEQ ID NO:34 and a nucleotide sequence as set forth in SEQ ID NO:35; q) a nucleotide sequence having the sequence as set forth in SEQ ID NO:36 and a nucleotide sequence as set forth in SEQ ID NO:37; r) a nucleotide sequence having the sequence as set forth in SEQ ID NO:38 and a nucleotide sequence as set forth in SEQ ID NO:39; s) a nucleotide sequence having the sequence as set forth in SEQ ID NO:40 and a nucleotide sequence as set forth in SEQ ID NO:41; t) a nucleotide sequence having the sequence as set forth in SEQ ID NO: 2 and a nucleotide sequence as set forth in SEQ ID NO:43; u) a nucleotide sequence having the sequence as set forth in SEQ ID NO:44 and a nucleotide sequence as set forth in SEQ ID NO:45; v) a nucleotide sequence having the sequence as set forth in SEQ ID NO:46 and a nucleotide sequence as set forth in SEQ ID NO: 7; w) a nucleotide sequence having the sequence as set forth in SEQ ID NO: 8 and a nucleotide sequence as set forth in SEQ ID NO: 9; x) a nucleotide sequence having the sequence as set forth in SEQ ID NO:50 and a nucleotide sequence as set forth in SEQ ID NO:51; y) a nucleotide sequence having the sequence as set forth in SEQ ID NO:52 and a nucleotide sequence as set forth in SEQ ID NO:53; z) a nucleotide sequence having the sequence as set forth in SEQ ID NO:54 and a nucleotide sequence as set forth in SEQ ID NO:55; aa) a nucleotide sequence having the sequence as set forth in SEQ ID NO:56 and a nucleotide sequence as set forth in SEQ ID NO:57; bb) a nucleotide sequence having the sequence as set forth in SEQ ID NO:58 and a nucleotide sequence as set forth in SEQ ID NO:59; cc) a nucleotide sequence having the sequence as set forth in SEQ ID NO:60 and a nucleotide sequence as set forth in SEQ ID NO:61; dd) a nucleotide sequence having the sequence as set forth in SEQ ID NO:62 and a nucleotide sequence as set forth in SEQ ID NO:63. Therefore, the invention further relates to an assay for measuring the subtle differences in genetic material regarding an added or omitted set of dinucleotide or tetranucleotide repeat polymorphisms selected from the group consisting of a sequence according to SEQ ID NO:7, a sequence according to SEQ ID NO:8 and a sequence according to SEQ ID NO:9, which comprises a. obtaining nucleotide segments comprising said repeat polymorphisms in an amount effective for testing, b. amplifying said segments by a PCR procedure using a pair of oligonucleotide primers capable of amplifying said polymorphism containing segments, c. resolving the amplified segments using page gels electrophoresis, and d. comparing the resolved segments by autoradiography to observe the differences in migration patterns due to length variation. Preferably, the invention further relates to an assay for measuring the subtle differences in genetic material regarding an added or omitted set of dinucleotide or tetranucleotide repeat polymorphisms selected from the group consisting of a sequence according to SEQ ID NO:7, a sequence according to SEQ ID NO:8 and a sequence according to SEQ ID NO:9, which comprises a. obtaining nucleotide segments comprising said repeat polymorphisms in an amount effective for testing, b. amplifying said segments by a PCR procedure using the pair of oligonucleotide primers selected from the group consisting of a sequence according to SEQ ID NO:l, a sequence according to SEQ ID NO:2, a sequence according to SEQ ID NO:3, a sequence according to SEQ ID NO:4, a sequence according to SEQ ID NO:5, or a sequence according to SEQ ID NO:6, c. resolving the amplified segments using page gels electrophoresis, and d. comparing the resolved segments by autoradiography to observe the differences in migration patterns due to length variation. Still further, the invention relates to an assay kit for conducting a PCR procedure comprising an effective amount of at least one nucleotide having a sequence according to the invention as set forth above, wherein the nucleotide is part of a primer pair of nucleotides selected from the group of nucleotide pairs consisting of a) a nucleotide sequence having the sequence as set forth in SEQ ID N0:1 and a nucleotide sequence as set forth in SEQ ID NO:2; b) a nucleotide sequence having the sequence as set forth in SEQ ID NO:3 and a nucleotide sequence as set forth in SEQ ID NO:4; and c) a nucleotide sequence having the sequence as set forth in SEQ ID NO:5 and a nucleotide sequence as set forth in SEQ ID NO:6, d) a nucleotide sequence having the sequence as set forth in SEQ ID NO:10 and a nucleotide sequence as set forth in SEQ ID NO:11; e) a nucleotide sequence having the sequence as set forth in SEQ ID NO:12 and a nucleotide sequence as set forth in SEQ ID NO:13; f) a nucleotide sequence having the sequence as set forth in SEQ ID NO:14 and a nucleotide sequence as set forth in SEQ ID NO:15; g) a nucleotide sequence having the sequence as set forth in SEQ ID NO:16 and a nucleotide sequence as set forth in SEQ ID NO:17; h) a nucleotide sequence having the sequence as set forth in SEQ ID NO:18 and a nucleotide sequence as set forth in SEQ ID NO:19; i) a nucleotide sequence having the sequence as set forth in SEQ ID NO:20 and a nucleotide sequence as set forth in SEQ ID NO:21? ) a nucleotide sequence having the sequence as set forth in SEQ ID NO:22 and a nucleotide sequence as set forth in SEQ ID NO:23; k) a nucleotide sequence having the sequence as set forth in SEQ ID NO:24 and a nucleotide sequence as set forth in SEQ ID NO:25; 1) a nucleotide sequence having the sequence as set forth in SEQ ID NO:26 and a nucleotide sequence as set forth in SEQ ID NO:27; m) a nucleotide sequence having the sequence as set forth in SEQ ID NO:28 and a nucleotide sequence as set forth in SEQ ID NO:29; n) a nucleotide sequence having the sequence as set forth in SEQ ID NO:30 and a nucleotide sequence as set forth in SEQ ID NO:31; o) a nucleotide sequence having the sequence as set forth in SEQ ID NO:32 and a nucleotide sequence as set forth in SEQ ID NO:33; p) a nucleotide sequence having the sequence as set forth in SEQ ID NO:34 and a nucleotide sequence as set forth in SEQ ID NO:35; q) a nucleotide sequence having the sequence as set forth in SEQ ID NO:36 and a nucleotide sequence as set forth in SEQ ID NO:37; r) a nucleotide sequence having the sequence as set forth in SEQ ID NO:38 and a nucleotide sequence as set forth in SEQ ID NO:39; s) a nucleotide sequence having the sequence as set forth in SEQ ID NO:40 and a nucleotide sequence as set forth in SEQ ID NO: 1; t) a nucleotide sequence having the sequence as set forth in SEQ ID NO:42 and a nucleotide sequence as set forth in SEQ ID NO:43; u) a nucleotide sequence having the sequence as set forth in SEQ ID NO:44 and a nucleotide sequence as set forth in SEQ ID NO: 5; v) a nucleotide sequence having the sequence as set forth in SEQ ID NO:46 and a nucleotide sequence as set forth in SEQ ID NO:47; w) a nucleotide sequence having the sequence as set forth in SEQ ID NO:48 and a nucleotide sequence as set forth in SEQ ID NO:49; x) a nucleotide sequence having the sequence as set forth in SEQ ID NO:50 and a nucleotide sequence as set forth in SEQ ID NO:51; y) a nucleotide sequence having the sequence as set forth in SEQ ID NO:52 and a nucleotide sequence as set forth in SEQ ID NO:53; z) a nucleotide sequence having the sequence as set forth in SEQ ID NO:54 and a nucleotide sequence as set forth in SEQ ID NO:55; aa) a nucleotide sequence having the sequence as set forth in SEQ ID NO:56 and a nucleotide sequence as set forth in SEQ ID NO:57; bb) a nucleotide sequence having the sequence as set forth in SEQ ID NO:58 and a nucleotide sequence as set forth in SEQ ID NO:59; cc) a nucleotide sequence having the sequence as set forth in SEQ ID NO:60 and a nucleotide sequence as set forth in SEQ ID NO:61; and dd) a nucleotide sequence having the sequence as set forth in SEQ ID NO:62 and a nucleotide sequence as set forth in SEQ ID NO:63; wherein said nucleotide is in combination with an effective amount of ancillary PCR reagents. Accordingly, the above described polymorphisms are useful for human sample individualization, because of their high PIC values. Since the described polymorphic systems are based on the polymerase chain reaction (PCR), only minute (40 nanograms) amounts of genomic DNA are required for each test. The target sequences range from 92 to 310 base pairs so that high molecular weight DNA is not necessary, and common problems such as shearing of DNA will have minimal impact on the performance of the assay. The assay is easy to perform and results can be obtained within 24 hours. It is not uncommon for results to be available within 3-4 hours. By comparison, the prior art methods require a number of days before results are available, usually 3-4 days are required. Also, the polymorphism corresponding to 1A-27A as described above and characterizes by their 27 primer pairs according to SEQ ID NO:10-SEQ NO:63 are useful for human sample individualization evaluation because of their high PIC values. Further, the assay according to the invention is able to detect very small differences in nucleotide sequences. A single omission or addition of the repeat sequence will change the mobility due to the electrical nature and molecular weight of the target nucleotide sequence. These differences are clearly visible on the autoradiographs after electrophoresis. Microsatellite repeat polymorphisms have been shown to be useful tools in DNA analysis. The three polymorphisms described here are original and are based on previously sequenced genes. The two tetranucleotide repeat markers described, can be scored easily since allele sizes differ by four base pairs. The most commonly used technique used in forensic screening is based on minisatellite markers, in distinction to the PCR able microsatellites described in the present invention. The general PCR technique step is conducted generally as described in U.S. Patent No. 4,683,195 to Mullis et al and U.S. Patent No. 4,683,202 to Mullis et al, which are hereby incorporated, by reference thereto. Further, electrical motility enhancing DNA analogs can optionally be used during the replication and amplification PCR procedure. The degree of polymorphism in the genetic segments according to the present invention, which polymorphisms yield highly informative identification test results, is surprising and unexpected. The high PIC value (approximately 0.9) is totally unexpected. Accordingly, the use of a PCR procedure and PCR primers pairs, such as those primer sequences according to SEQ ID NO:l to SEQ ID NO:6, to detect the polymorphism DNA segment according to the present invention yields excellent results. Further use of primer sequences corresponding to SEQ ID NO:10 through SEQ ID NO:63 to detect the polymorphism yields excellent results. Such results are sufficiently accurate and informative to accurately identify DNA segments and determine degrees of relationship between DNA segments of individuals. Moreover, conducting three sets of PCR procedures on the same DNA segment samples while using a different PCR primer pair according to the present invention for each of the three procedures yields extraordinarily accurate and informative test results. Comparison of the three sets of test results data provides extremely accurate DNA segment identification. The following examples are provided to more specifically describe the invention which is not limited to the following examples. The described oligonucleotide primers are used to amplify the target sequences using PCR, under the following conditions: Example 1 The samples are of DNA are prepared as follows. 60ng of genomic DNA are used as template for PCR with 80ng of each oligonucleotide primer, 0.6 units of Taq Polymerase 50mM KCL, lOmM Tris (pH 8.3), 1.5mM MgCl,, 0.01% gelatin, 200uM of each dGTP, dATP, dTTP, 2.5uM dCTP and 10 icrocuries of alpha P32 dCTP., in a final reaction volume of 15 microliters. The samples are overlaid with 15 microliters of mineral oil to prevent evaporation. Example 2 PCR is performed for each of the samples and primers described in Example 1, above. PCR is performed in a Techne MW-1 microplate thermocycler under the following conditions denaturation of 94 degrees C for 1.4 min., annealing at 55 degrees C for 2 min., and extension at 72 degrees C for 2 min. The cycle is repeated 30 times with a final extension at 72 degrees C for 10 min. ffxample 3 The amplified DNA segments from each of the samples described in Example 2 above are resolved by electrophoresis as follows. Two microliters of each PCR reaction mixture sample are electrophoresed on a 6% PAGE sequencing gel and visualized by autoradiography. Exposure times for the autoradiography range from 3-16 hours. The foregoing descriiption of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without departing from the generic concept and therefore such adaptations are intended to be comprehended within the meaning and range of equivalents of a disclosed embodiment. It is to be understood that the phraseology or terminology employed herein is for the purposes of description only and not of limitation.

Claims: Claims 1. A nucleotide sequence selected from the group consisting of a sequence according to SEQ ID N0:1, a sequence according to SEQ ID NO: 2, a sequence according to SEQ ID NO:3, a sequence according to SEQ ID NO:4, a sequence according to SEQ ID NO:5, or a sequence according to SEQ ID NO:6. 2. A nucleotide sequence according to claim 1, wherein the sequence is a sequence according to SEQ ID NO:l. 3. A nucleotide sequence according to claim 1, wherein the sequence is a sequence according to SEQ ID NO:2. 4. A nucleotide sequence according to claim 1, wherein the sequence is a sequence according to SEQ ID NO:3. 5. A nucleotide sequence according to claim 1, wherein the sequence is a sequence according to SEQ ID NO:4. 6. A nucleotide sequence according to claim 1, wherein the sequence is a sequence according to SEQ ID NO:5. ZG 7. A nucleotide sequence according to claim 1, wherein the sequence is a sequence according to SEQ ID NO:6. 8. A method for conducting a PCR procedure comprising using an effective amount of at least one nucleotide according to claim 1, wherein the nucleotide is part of a primer pair of nucleotides selected from the group of nucleotide pairs consisting of a) a nucleotide sequence having the sequence as set forth in SEQ ID N0:1 and a nucleotide sequence as set forth in SEQ ID NO:2; b) a nucleotide sequence having the sequence as set forth in SEQ ID NO:3 and a nucleotide sequence as set forth in SEQ ID NO:4; and c) a nucleotide sequence having the sequence as set forth in SEQ ID NO:5 and a nucleotide sequence as set forth in SEQ ID NO:6. 9. An assay for measuring the subtle differences in genetic material regarding an added or omitted set of dinucleotide or tetranucleotide repeat polymorphisms wherein said genetic material comprises a sequence selected from the group consisting of a sequence according to SEQ ID NO: 1 , a sequence according to SEQ ID NO:8 and a sequence according to SEQ ID NO:9, which comprises a. obtaining nucleotide segments comprising said repeat polymorphisms in an amount effective for testing, b. amplifying said segments by a PCR procedure using a pair of oligonucleotide primers capable of amplif ing said polymorphism containing segments, c. resolving the amplified segments using page gels electrophoresis, and d. comparing the resolved segments by autoradiography to observe the differences in migration patterns due to length variation. 10. An assay according to claim 9, wherein said pair of oligonucleotide primers is selected from the group consisting of a sequence according to SEQ ID NO:l, a sequence according to SEQ ID NO:2, a sequence according to SEQ ID NO:3, a sequence according to SEQ ID NO:4, a sequence according to SEQ ID NO:5, or a sequence according to SEQ ID NO:6. 11. An assay kit for conducting a PCR procedure comprising an effective amount of at least one nucleotide having a sequence according to claim 1, wherein the nucleotide is part of a primer pair of nucleotides selected from the group of nucleotide pairs consisting of a) a nucleotide sequence having the sequence as set forth in SEQ ID NO:l and a nucleotide sequence as set forth in SEQ ID NO:2; b) a nucleotide sequence having the sequence as set forth in SEQ ID NO:3 and a nucleotide sequence as set forth in SEQ ID NO:4; and c) a nucleotide sequence having the sequence as set forth in SEQ ID NO:5 and a nucleotide sequence as set forth in SEQ ID NO:6, in combination with an effective amount of ancillary PCR reagents. 12. A nucleotide sequence selected from the group consisting of a sequence according to SEQ ID NO:10 through SEQ ID NO:63. 13. A method for conducting a PCR procedure comprising using an effective amount of at least one nucleotide according to claim 12, wherein the nucleotide is part of a primer pair of nucleotides selected from the group of nucleotide pairs consisting of d) a nucleotide sequence having the sequence as set forth in SEQ ID NO:10 and a nucleotide sequence as set forth in SEQ ID NO:11; e) a nucleotide sequence having the sequence as set forth in SEQ ID NO:12 and a nucleotide sequence as set forth in SEQ ID NO:13; f) a nucleotide sequence having the sequence as set forth in SEQ ID NO:14 and a nucleotide sequence as set forth in SEQ ID NO:15; g) a nucleotide sequence having the sequence as set forth in SEQ ID NO:16 and a nucleotide sequence as set forth in SEQ ID NO:17; h) a nucleotide sequence having the sequence as set forth in SEQ ID NO:18 and a nucleotide sequence as set forth in SEQ ID NO:19; i) a nucleotide sequence having the sequence as set forth in SEQ ID NO:20 and a nucleotide sequence as set forth in SEQ ID NO:21; j) a nucleotide sequence having the sequence as set forth in SEQ ID NO:22 and a nucleotide sequence as set forth in SEQ ID NO:23; k) a nucleotide sequence having the sequence as set forth in SEQ ID NO:24 and a nucleotide sequence as set forth in SEQ ID NO:25; 1) a nucleotide sequence having the sequence as set forth in SEQ ID NO:26 and a nucleotide sequence as set forth in SEQ ID NO:27; m) a nucleotide sequence having the sequence as set forth in SEQ ID NO:28 and a nucleotide sequence as set forth in SEQ ID NO:29; n) a nucleotide sequence having the sequence as set forth in SEQ ID NO:30 and a nucleotide sequence as set forth in SEQ ID NO:31; o) a nucleotide sequence having the sequence as set forth in SEQ ID NO:32 and a nucleotide sequence as set forth in SEQ ID NO:33; p) a nucleotide sequence having the sequence as set forth in SEQ ID NO:34 and a nucleotide sequence as set forth in SEQ ID NO:35; q) a nucleotide sequence having the sequence as set forth in SEQ ID NO:36 and a nucleotide sequence as set forth in SEQ ID NO:37; r) a nucleotide sequence having the sequence as set forth in SEQ ID NO:38 and a nucleotide sequence as set forth in SEQ ID NO:39; s) a nucleotide sequence having the sequence as set forth in SEQ ID NO:40 and a nucleotide sequence as set forth in SEQ ID NO:41; t) a nucleotide sequence having the sequence as set forth in SEQ ID NO:42 and a nucleotide sequence as set forth in SEQ ID NO:43; u) a nucleotide sequence having the sequence as set forth in SEQ ID NO:44 and a nucleotide sequence as set forth in SEQ ID NO:45; v) a nucleotide sequence having the sequence as set forth in SEQ ID NO:46 and a nucleotide sequence as set forth in SEQ ID NO:47; w) a nucleotide sequence having the sequence as set forth in SEQ ID NO:48 and a nucleotide sequence as set forth in SEQ ID NO:49; x) a nucleotide sequence having the sequence as set forth in SEQ ID NO:50 and a nucleotide sequence as set forth in SEQ ID NO:51; y) a nucleotide sequence having the sequence as set forth in SEQ ID NO:52 and a nucleotide sequence as set forth in SEQ ID NO:53; z) a nucleotide sequence having the sequence as set forth in SEQ ID NO:54 and a nucleotide sequence as set forth in SEQ ID NO:55; aa) a nucleotide sequence having the sequence as set forth in SEQ ID NO:56 and a nucleotide sequence as set forth in SEQ ID NO:57; bb) a nucleotide sequence having the sequence as set forth in SEQ ID NO:58 and a nucleotide sequence as set forth in SEQ ID NO:59; cc) a nucleotide sequence having the sequence as set forth in SEQ ID NO:60 and a nucleotide sequence as set forth in SEQ ID NO:61; and dd) a nucleotide sequence having the sequence as set forth in SEQ ID NO:62 and a nucleotide sequence as set forth in SEQ ID NO:63; 14. An assay for measuring the subtle differences in genetic material regarding an added or omitted set of dinucleotide or tetranucleotide repeat polymorphisms wherein said genetic material comprises a sequence characterized by primer pairs 1A-27A, which comprises a. obtaining nucleotide segments comprising said repeat polymorphisms in an amount effective for testing, b. amplifying said segments by a PCR procedure using a pair of oligonucleotide primers capable of amplifying said polymorphism containing segments, c. resolving the amplified segments using page gels electrophoresis, and d. comparing the resolved segments by autoradiography to observe the differences in migration patterns due to length variation. 15. An assay according to claim 3, wherein said pair of oligonucleotide primers is selected from the group consisting of a sequence according to SEQ ID NO:10 through SEQ ID NO:63. 16. An assay kit for conducting a PCR procedure comprising an effective amount of at least one nucleotide having a sequence according to claim 1, wherein the nucleotide is part of a primer pair of nucleotides selected from the group of nucleotide pairs consisting of d) a nucleotide sequence having the sequence as set forth in SEQ ID NO:10 and a nucleotide sequence as set forth in SEQ ID NO:11; e) a nucleotide sequence having the sequence as set forth in SEQ ID NO:12 and a nucleotide sequence as set forth in SEQ ID NO:13; f) a nucleotide sequence having the sequence as set forth in SEQ ID NO:14 and a nucleotide sequence as set forth in SEQ ID NO:15; g) a nucleotide sequence having the sequence as set forth in SEQ ID NO:16 and a nucleotide sequence as set forth in SEQ ID NO:17; h) a nucleotide sequence having the sequence as set forth in SEQ ID NO:18 and a nucleotide sequence as set forth in SEQ ID NO:19; 31 i) a nucleotide sequence having the sequence as set forth in SEQ ID NO:20 and a nucleotide sequence as set forth in SEQ ID NO:21; ) a nucleotide sequence having the sequence as set forth in SEQ ID NO:22 and a nucleotide sequence as set forth in SEQ ID NO:23; k) a nucleotide sequence having the sequence as set forth in SEQ ID NO:24 and a nucleotide sequence as set forth in SEQ ID NO:25; 1) a nucleotide sequence having the sequence as set forth in SEQ ID NO:26 and a nucleotide sequence as set forth in SEQ ID NO:27; m) a nucleotide sequence having the sequence as set forth in SEQ ID NO:28 and a nucleotide sequence as set forth in SEQ ID NO:29; n) a nucleotide sequence having the sequence as set forth in SEQ ID NO:30 and a nucleotide sequence as set forth in SEQ ID NO:31; o) a nucleotide sequence having the sequence as set forth in SEQ ID NO:32 and a nucleotide sequence as set forth in SEQ ID NO:33; p) a nucleotide sequence having the sequence as set forth in SEQ ID NO:34 and a nucleotide sequence as set forth in SEQ ID NO:35; q) a nucleotide sequence having the sequence as set forth in SEQ ID NO:36 and a nucleotide sequence as set forth in SEQ ID NO:37; r) a nucleotide sequence having the sequence as set forth in SEQ ID NO:38 and a nucleotide sequence as set forth in SEQ ID NO:39; s) a nucleotide sequence having the sequence as set forth in SEQ ID NO:40 and a nucleotide sequence as set forth in SEQ ID NO:41; t) a nucleotide sequence having the sequence as set forth in SEQ ID NO:42 and a nucleotide sequence as set forth in SEQ ID NO:43; u) a nucleotide sequence having the sequence as set forth in SEQ ID NO:44 and a nucleotide sequence as set forth in SEQ ID NO:45; v) a nucleotide sequence having the sequence as set forth in SEQ ID NO:46 and a nucleotide sequence as set forth in SEQ ID NO:47; w) a nucleotide sequence having the sequence as set forth in SEQ ID NO:48 and a nucleotide sequence as set forth in SEQ ID NO:49; x) a nucleotide sequence having the sequence as set forth in SEQ ID NO:50 and a nucleotide sequence as set forth in SEQ ID NO:51; y) a nucleotide sequence having the sequence as set forth in SEQ ID NO:52 and a nucleotide sequence as set forth in SEQ ID NO:53; z) a nucleotide sequence having the sequence as set forth in SEQ ID NO:54 and a nucleotide sequence as set forth in SEQ ID NO:55; aa) a nucleotide sequence having the sequence as set forth in SEQ ID NO:56 and a nucleotide sequence as set forth in SEQ ID NO:57; bb) a nucleotide sequence having the sequence as set forth in SEQ ID NO:58 and a nucleotide sequence as set forth in SEQ ID NO:59; cc) a nucleotide sequence having the sequence as set forth in SEQ ID NO:60 and a nucleotide sequence as set forth in SEQ ID NO:61; and dd) a nucleotide sequence having the sequence as set forth in SEQ ID NO:62 and a nucleotide sequence as set forth in SEQ ID NO:63; wherein said effective amount of said nucleotide combination with an effective amount of ancillary eagents.

Inventors: MERRILL CARL R, POLYMEROPOULOS MICHAEL H, MERRILL, CARL, R., POLYMEROPOULOS, MICHAEL, H.
Applicants: US OF AMERICA AS PRESENTED BY, THE UNITED STATES OF AMERICA, AS PRESENTED BY THE
Application year: 1992
Main classification: C07H21
IPC codes: C12N15, C12Q1